CHR Chr. Hansen Holding A/S

Chr. Hansen Holding A/S - Major shareholder announcement from EuroPacific Growth Fund

Chr. Hansen Holding A/S - Major shareholder announcement from EuroPacific Growth Fund

Company Announcement No. 25/2019

November 14, 2019



For further information please contact:

Martin Riise, Senior Director, Investor Relations, Tel:

Annika Stern, Investor Relations Officer, Tel:

Camilla Lercke, Head of Media Relations, Tel:



Attachment

EN
14/11/2019

Underlying

CHRChr. Hansen Holding A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Chr. Hansen Holding A/S

Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
CHR Chr. Hansen Hol...

Chr. Hansen (No_rec, TP: DKK) - Discontinuing coverage

We have discontinued coverage of Chr. Hansen in light of its combination with Novozymes. Our last published recommendation, target price, and estimates should no longer be relied upon.

CHR CHR. HANSEN HOLDING A/S
02/02/24 February 2, 2024 1 EN
 PRESS RELEASE
Free
CHR Chr. Hansen Hol...

Completion of the combination between Novozymes and Chr. Hansen

Completion of the combination between Novozymes and Chr. Hansen January 29, 2024 – Company announcement no. 2 Please see attachment. CONTACT INFORMATION Investor Relations Tobias Cornelius Bjorklund Anders Enevoldsen Press Relations Lina Danstrup Attachment

January 29, 2024 1 EN
 PRESS RELEASE
Free
CHR Chr. Hansen Hol...

All necessary regulatory approvals have been obtained for the combinat...

All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen January 26, 2024 – Company announcement no. 1 Please see attachment. Contact information Investor RelationsDisa Tuominen Press RelationsSanne Seyer-Hansen Attachment

January 26, 2024 1 EN
Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
CHR Chr. Hansen Hol...

Chr. Hansen (Hold, TP: DKK582.00) - Down to HOLD, target price raised

We forecast Chr. Hansen to reach the high end of its 2023 guidance of 10–12% organic revenue growth and a 26–27% EBIT margin, but expect the combined entity (Novonesis) to issue a new guidance upon completion of the merger. As Chr. Hansen shareholders are set to receive 1.5236 new B-shares in Novonesis, the changes in our Novozymes model translate into a raised Chr. Hansen target price of DKK582 (536), and we have thus downgraded to HOLD (BUY).

CHR CHR. HANSEN HOLDING A/S
01/16/24 January 16, 2024 1 EN
 PRESS RELEASE
Free
CHR Chr. Hansen Hol...

Update on the merger approval process for the combination of Novozymes...

Update on the merger approval process for the combination of Novozymes and Chr. Hansen: South Korean merger approval granted December 20, 2023 Please see attachment. Contact information Investor RelationsDisa Tuominen Press RelationsSanne Seyer-Hansen Attachment

December 20, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch